- Acutus Medical, Inc.’s superior contactless mapping technology threatens to change and expand the ablation treatment paradigm for cardiac arrhythmias.
- However, the company’s launch has been disappointing with the pandemic being held out as the scapegoat.
- With a new chief commercial officer, differentiated technology, a $5.5 billion TAM, and beneficial owner buying on its recent secondary, this busted IPO merited a deeper dive.
- A full investment analysis and recommendation follow in the paragraphs below.
For further details see:
Acutus Medical: A Name To Slowly Accumulate